Status:

COMPLETED

Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome

Lead Sponsor:

St. Jude Children's Research Hospital

Conditions:

Wiskott-Aldrich Syndrome

Eligibility:

MALE

Up to 18 years

Phase:

PHASE1

Brief Summary

Wiskott - Aldrich syndrome (WAS) is a rare disorder curable only through allogeneic hematopoietic stem cell transplantation. A mismatched family member is an option when no human leukocyte antigen (HL...

Detailed Description

Secondary Objectives in this trial include the following: * To estimate the survival of study recipients at one year after infusion of the T- and B-lymphocyte depleted stem cell graft. * To assess if...

Eligibility Criteria

Inclusion

  • Genotypical diagnosis of Wiskott-Aldrich Syndrome.
  • Less than 18 years of age at time of transplant.
  • Must meet two of the eight following clinical criteria:
  • Eczema that is refractory to standard therapy.
  • Thrombocytopenia as defined by a platelet count \< 50,000/mm3.
  • Significant risk for or presence of opportunistic infection.
  • Autoimmune disease.
  • Malignancy or pre-malignant condition.
  • Family history as defined as a family member with WAS who died before 10 years of age.
  • Does not have a suitable, available 6/6 HLA-matched sibling donor available for donation.
  • Does not have a suitable, available 10/10 HLA-allele matched unrelated donor identified through the National Marrow Donor Program (NMDP).

Exclusion

  • If any of the following clinical indicators are met within 45 days prior to transplant, the research participant will not be eligible for the study:
  • Symptomatic cardiac disease or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction \< 30%).
  • Creatinine clearance or Tc 99 less than or equal 40ml/min/1.73 m2.
  • SGPT greater than or equal 500 U/L.
  • Karnofsky or Lansky Performance Score of \< 50.
  • Pulmonary function tests: FVC \< 50% of predicted value if age appropriate to perform the testing adequately or an O2 saturation less than or equal to 92% on room air at rest.

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2009

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT00160355

Start Date

May 1 2005

End Date

February 1 2009

Last Update

April 26 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome | DecenTrialz